Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Litigation settlement reached over Insmed growth drug
The litigation includes the patent infringement suits brought by Tercica and Genentech against Insmed and an unfair business practices suit. The companies agreed that the drug Iplex should
The litigation includes the patent infringement suits brought by Tercica and Genentech against Insmed and an unfair business practices suit. The companies agreed that the drug Iplex should
It is intended that the headcount will be reduced from 260 by approximately 15% during this year across the organization. Acambis has appointed a new chief executive officer
ZymoGenetics said the decision would shorten the timeline for offering spray rhThrombin by about 18 months and save substantial amounts of money for the company. ZymoGenetics now plans
The clinical phase II study is a dose-ranging trial to evaluate the efficacy of ABT-894 in attention deficit-hyperactivity disorder (ADHD) patients. The first patients have been enrolled and
Preliminary results from the phase II trial, conducted by Wyeth, showed that the initial formulation of oral methylnaltrexone was generally well tolerated but did not exhibit sufficient clinical
The study conducted in collaboration with Institut Curie will seek to enroll around 20 patients. The goal of this study is to evaluate pharmacokinetic, the safety and the
Despite its failure to provide effectiveness for acute coronary syndrome (ACS), CV said there was no adverse trend in death or arrhythmias in patients on Ranexa. The company
Avalon will use its AvalonRx platform to screen a select set of compounds from Merck's proprietary compound library and identify hits against this target. It has not been
Moli1901 is being developed by AOP Orphan in Europe under a licensing and commercialization agreement with Lantibio. The study was designed to investigate safety and tolerability of aerosolized
The safer aspirin PA 325 is a patented formulation of 325mg of aspirin surrounded by a 20mg coating of an immediate release formulation of a proton pump inhibitor.